follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
compani today report result fourth quarter full year end dec provid financi
guidanc
baxter continu build momentum deliv solid top-lin strong bottom-lin perform
year said jo almeida chairman chief execut offic focu increas innov
combin divers portfolio global footprint unwav financi disciplin help us maintain
trajectori dynam marketplac
almeida ad on-going busi transform continu throughout prepar launch new
product pursu high-valu capit deploy opportun deliv addit oper excel
initi goal remain drive top quartil perform stakehold line mission
world-wide sale fourth quarter total approxim billion increas percent report basi
percent constant currenc basi oper basi compar prior-year period oper
sale fourth quarter adjust impact foreign exchang gener competit
cyclophosphamid well compani acquisit two surgic product plc close
march
sale total billion increas percent report basi percent oper basi
sale billion increas percent report basi percent constant currenc
oper basi driver growth quarter includ baxter renal advanc
surgeri acut therapi busi increas demand baxter contract manufactur servic also
contribut perform quarter
pleas see attach schedul accompani press releas addit detail sale perform
quarter includ breakout baxter three geograph segment six global busi unit gbu
baxter report incom continu oper million per dilut share gener
accept account principl basi fourth quarter result includ special item total million
after-tax primarili relat busi optim intang amort adjust basi baxter fourth
quarter incom continu oper total million per dilut share adjust earn per
dilut share advanc percent quarter driven solid oper perform on-going benefit
compani busi transform effort lower pension expens
baxter world-wide sale total approxim billion increas percent report basi
percent constant currenc basi percent oper basi compar oper sale
adjust impact foreign exchang gener competit cyclophosphamid compani
march acquisit two surgic product plc compani juli acquisit
sale total billion increas percent report basi percent oper basi
sale billion increas percent report basi percent constant currenc
oper basi
year advanc surgeri acut therapi busi deliv double-digit
growth constant currenc rate renal achiev mid-single-digit growth constant currenc basi
growth help off-set low-single-digit declin compani medic deliveri clinic nutrit
busi accompani schedul includ addit detail sale perform geograph segment
gbu
baxter report incom continu oper billion per dilut share basi
result includ special item total million after-tax primarili due busi optim intang
amort partial off-set benefit relat compani foreign credit defer tax asset
adjust basi baxter incom continu oper total billion per dilut share
increas percent prior-year period
baxter gener billion oper cash flow driven improv oper perform
continu impact program focus improv compani work capit result compani
gener billion free cash flow oper cash flow less capit expenditur million year
baxter sustain improv cash gener give us flexibl evalu pursu grow rang
organ inorgan growth opportun said jay saccaro chief financi offic also augment abil
return valu directli sharehold increas annual dividend rate approxim
percent paid million dividend repurchas billion share
baxter achiev notabl mileston pursuit mission patient well emphasi
acceler profit growth among highlight past year compani
announc collabor mayo clinic establish renal care center excel serv patient
across continuum care chronic kidney diseas ckd manag transplant drive better
outcom center locat mayo clinic jacksonvil fla campu
launch baxter kaguya autom periton dialysi system japan incorpor sever distinct
featur reflect local need patient demograph provid valuabl new in-hom treatment option
market histor emphas in-cent hemodialysi
receiv ce mark prismax system baxter next gener technolog continu renal replac
organ support therapi
launch two innov drug infus pump meet uniqu need market around world
spectrum iq infus dose iq safeti softwar canada evo iq infus
global market
expand gener inject pharmaceut portfolio multipl new product includ dexmedetomidin
hydrochlorid percent sodium chlorid use baxter proprietari galaxi contain technolog
repres first present premix formul flexibl shelf-stabl ready-to-us
launch eight new product expand breadth impact baxter advanc surgeri portfolio
recent includ new dispos curv applic floseal hemostat matrix product line provid
surgeon greater control ent surgeri
acquir two product plc recothrom thrombin topic recombin preveleak
surgic sealant broaden baxter advanc surgeri portfolio hemostat sealant
introduc olimel olive-bas standard parenter nutrit solut highest protein
announc appoint two new member baxter board director bring leadership expertis
support compani on-going transform
patricia patti morrison former execut vice presid chief inform offic whose
vast inform technolog expertis help advanc baxter digit health strategi
wendel former covidien senior vice presid strategi busi develop whose experi
asset baxter continu evalu potenti inorgan growth opportun
baxter progress continu reflect addit highlight open year recent
began patient treatment clinic trial baxter on-demand periton dialysi pd solut
gener system innov technolog design improv patient experi simplifi therapi
manag make pd solut small batch patient home
patient manag telehealth platform embed compani amia kaguya homechoic
addit baxter continu recogn commit corpor social respons workplac
excel compani recent
name forb capit list america best corpor citizen
name forb list best employ divers
compani would also like note unit state depart justic washington crimin section
anti-trust divis advis baxter offici close grand juri investig salin market
baxter longer subject target investig
full-year baxter expect sale growth percent report basi percent constant
currenc basi percent oper basi compani expect adjust earn continu
oper special item per dilut share
first-quart compani expect sale declin approxim percent report basi
increas approxim percent constant currenc basi grow approxim percent
oper basi compani expect adjust earn continu oper special item
per dilut share
full-year first-quart oper sale estim adjust impact foreign exchang
gener competit cyclophosphamid
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
baxter touch million live everi day product servic essenti build block healthcar
youll find baxter product therapi nearli everi floor everi depart almost everi hospit
world-wide youll find us clinic home
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
abbott global diversifi healthcar compani central purpos help peopl live healthiest possibl
live offer broad portfolio market-lead product align favor long-term healthcar trend
develop develop market build strong foundat year success abbott
pois deliv top-tier growth expand margin strong cash flow increas return sharehold
januari found global biopharmaceut compani focu capabl
address world greatest health challeng stabil resourc expertis passion
discov develop bring market groundbreak scienc solv biggest health problem face
world today tomorrow
one world lead biotechnolog compani values-bas compani deepli root
scienc innov transform new idea discoveri medicin patient seriou ill
commit unlock potenti biolog patient suffer seriou ill discov
develop manufactur deliv innov human therapeut approach begin use tool like
advanc human genet unravel complex diseas understand fundament human biolog
bausch health compani inc formerli valeant pharmaceut multi-national specialti pharmaceut
compani base laval canada bausch health focus improv peopl live health care
product deliv commit patient health care provid stakehold societi
build innov compani dedic advanc global health
manufactur market broad rang brand gener pharmaceut over-the-count over-the-counter
product medic devic contact lens intraocular lens ophthalm surgic equip aesthet
devic directli indirectli countri region includ unit state canada europ
middl east africa asia pacif latin america day product use million peopl
around world
bristol-my squibb global biopharma compani firmli focus mission discov develop deliv
innov medicin help patient prevail seriou diseas bristol-my squibb uk aim deliv
commit patient custom employe commun environ
 compani found colonel eli lilli man commit creat high-qual medicin
meet real need centuri later passion build preced continu
pursuit make life better individu commun world around us
found year ago genentech lead biotechnolog compani discov develop
manufactur commerci medicin treat patient seriou life-threaten medic condit
compani member roch group headquart south san francisco california
johnson johnson famili compani engag research develop manufactur
sale broad rang product health care field virtual countri world johnson johnson
primari interest histor current product relat human health well-b
johnson johnson incorpor state new jersey
base unit state distribut health care system medic suppli pharmaceut
product also provid specialti pharmaceut solut biotech pharmaceut manufactur well
practic manag technolog clinic support oncolog specialti practic addit
deliv comprehens offer healthcar product technolog equip relat servic non-
hospit market includ physician offic surgeri center long-term care facil home healthcar
merck compani inc american pharmaceut compani one largest pharmaceut compani
world compani establish unit state subsidiari german compani merck
found merck famili global healthcar compani histori work
make differ compani known merck unit state canada everywher els known
msd base kenilworth oper countri
novarti intern ag swiss multi-national pharmaceut compani base basel switzerland novarti
creat merger ciba-geigi sandoz novarti predecessor compani trace
root back year rich histori develop innov product novarti manufactur
lamisil other
novo nordisk global healthcar compani year innov leadership diabet care
compani aim provid medic treat wide rang diseas obes haemophilia growth
disord seriou chronic diseas base denmark novo nordisk employ approxim
peopl countri market product countri
open first manufactur facil michigan sign first larg private-label
custom pave way convers re-packag home remedi manufactur
afford health care product shift strateg direct drove growth next sever
decad becam foundat compani mission today perrigo world largest manufactur
over-the-counter healthcar product supplier infant formula store brand market compani also lead
provid brand over-the-counter product throughout europ well lead produc extend
topic prescript drug headquart ireland sell product primarili north america
europ well market includ australia israel china
cousin charl pfizer charl erhart found charl pfizer compani red brick build
brooklyn ny one world largest pharmaceut compani list new york stock
exchang share compon jone industri averag sinc leader
american chemic busi mark anniversari portfolio includ wide array industri
pharmacolog product anchor citric acid camphor cream tartar borax iodin compani
offic new york chicago contact import-export busi crisscross world
regeneron pharmaceut inc lead scienc technolog compani deliv life-
transform medicin seriou diseas inc compani headquart eastview
near tarrytown new york found physician-scientist year ago science-driven approach result
six fda-approv medicin numer product candid rang diseas includ asthma pain
cancer infecti diseas
sanofi french multi-national pharmaceut compani headquart pari franc world
fifth-largest prescript sale sanofi employe repres nation
oncolog thrombosi vaccin world largest produc latter subsidiari sanofi
teva establish global headquart base israel today portfolio
molecul produc approxim billion tablet capsul year manufactur facil
rank among lead pharmaceut compani world activ countri approxim
employe around world dedic mission
pharmaceut industri compris compani engag research develop manufactur
distribut drug human veterinari use new drug enorm posit influenc global health
prosper econom product save live increas life span reduc suffer prevent surgeri
shorten hospit stay advanc medicin elimin deadli diseas brought life-
threaten condit control drug therapi integr part nearli everi facet healthcar new
breakthrough promis revolution treatment non-communic diseas
sake simplic unless otherwis note pharmaceut drug medicin report refer
innov gener product chemicallyderiv biologically-deriv product prescription-bas
over-the-count product breakdown pharmaceut product sector
biopharmaceut drug medicin defin substanc intend use
diagnosi cure mitig treatment prevent diseas substanc food intend affect
structur function bodi drug produc form pill tablet capsul vial ointment
powder solut suspens
innov origin chemically-deriv drug develop extens clinic trial
human anim innov reli patent regulatori data protect form intellectu
properti right ipr justifi invest requir bring product market patent term year
drug elig least five year market exclus depend time patent valid
 food drug administr fda approv pharmaceut industri heavili depend
develop new molecul replac revenu stream older drug approach expir
patent term price new drug design cover past futur expenditur gener drug
copi innov pharmaceut contain activ ingredi ident strength dosag
form rout administr unit state upon either patent expir success challeng
relev patent manufactur produc gener drug long meet fda approv bioequival
standard gener compani typic focu high volum earn profit requir effici product method
distribut chain
gener sold chemic name known commod gener commod gener often
manufactur one compani compet mainli price brand gener market drug
compani label typic command higher price non-brand gener
larg diversifi global pharmaceut industri one critic competit sector
economi accord pharmaceut research manufactur associ phrma
peopl work biopharmaceut industri unit state across broad rang occup
scientif research technic support manufactur directli indirectli industri support
million job across unit state ad estim billion economi although
manufactur job support industri expect declin next decad due continu
product gain remain import sourc high pay job provid salari way nation
research develop
pharmaceut sector consist one intens industri unit state
research-bas industri gener alloc around percent revenu activ invest
billion although unit state remain global leader innov invest
produc half world new molecul last decad continu leadership taken
grant perform unit state becom increasingli expens rel emerg economi
asia china singapor govern enact polici attract invest pois
futur growth condit limit offshor past market proxim avail
talent rapidli shift
unit state one world support domest environ develop
commerci pharmaceut minim market barrier strength includ intellectu properti
system reward innov patent data protect science-bas regulatori system
consid rigor world world largest scientif research base foster academ
institut decad govern research fund robust capit market unit state attract
major global ventur capit invest start-up biopharmaceut enterpris
addit favor ip regulatori environ law allow direct-to-consum advertis creat
immens demand specif patent importantli unit state world largest free-pric
market pharmaceut result price compar high make lower profit countri
cover cost unit state also high per capita incom unmatch access healthcar
larg elderli popul cultur end-of-lif prolong high rate chronic diseas drug consumpt
strong consum prefer innov drug factor contribut far world
largest pharmaceut market billion sale tripl size nearest rival china
unit state remain world import market forese futur healthi growth expect
across product sector
 depart commerc intern trade administr
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
